|
|
AT A GLANCEGlossary |
|
|
Introduction |
|
|
Welcome to the UCSF AGRC course in Geriatrics and Gerontology |
|
|
Course Topics |
|
|
Overall Course Goals |
|
|
Philosophy |
|
|
Faculty |
|
|
Why Take This Course? |
|
|
The Multifaceted Face of Aging: 3 Cases |
|
|
Discussion of the Three Preceding Cases |
|
|
How To Use This Course |
|
|
Where To Start? |
|
|
Then What? |
|
|
How to Start--Case 1 |
|
|
How to Start--Case 2 |
|
|
Reflection on Two Cases |
|
|
Post Test |
|
|
Demography And Epidemiology |
|
|
The Changing Face of Aging: Objectives |
|
|
Local and Regional Variations Among Older Adults in the United States |
|
|
Implications of an Aging Society for Health Care Needs and Resources |
|
|
Common Chronic Conditions Associated with Advanced Age |
|
|
Post Test |
|
|
Biology and Physiology of Aging |
|
|
Introduction and Background |
| 2.1.1 | Table of Contents |
| 2.1.2 | Module Learning Objectives |
| 2.1.3 | Personal Exercise |
| 2.1.4 | Case Background |
| 2.1.5 | Historical View of Aging |
| 2.1.6 | Successful Aging |
| 2.1.7 | What is the Truth about Aging? |
| 2.1.8 | When Pathologies are Attributed to Aging |
| 2.1.9 | Aging or Disease? |
| 2.1.10 | Understanding Age-Related Changes |
|
|
Theories of Aging |
|
|
Physiological Changes with Aging |
|
|
Pharmacologic Considerations |
|
|
Post Test |
|
|
Socio-cultural And Psychologicial… |
|
|
Module Objectives |
|
|
Social Theories of Aging |
| 3.2.1 | Modernization Theory |
| 3.2.2 | Modernization Theory (II) |
| 3.2.3 | Criticisms of Modernization Theory |
| 3.2.4 | Role Theory |
| 3.2.5 | Role Theory (II) |
| 3.2.6 | Criticisms of Role Theory |
| 3.2.7 | Disengagement Theory |
| 3.2.8 | Activity Theory |
| 3.2.9 | Reflections (III) |
|
|
Psychological Development In Late Life |
|
|
Ethno-Cultural Issues And Age-Stratified Societies |
|
|
Late-Life Transitions |
| 3.5.1 | Normative Transitions in Later Life |
| 3.5.2 | "Off Time" Transitions |
| 3.5.3 | Reflections (VII) |
|
|
Dependent Elders: Special Concerns |
| 3.6.1 | Adult Guardianship in Euro-American Societies |
| 3.6.2 | Elder Abuse |
| 3.6.3 | Caregiving: Informal |
| 3.6.4 | Caregiving: Formal |
| 3.6.5 | Residential Care |
| 3.6.6 | Ageism and Therapeutic Nihilism |
|
|
Cultural Views of Death |
| 3.7.1 | Funeral Rites |
| 3.7.2 | The "Good Death" |
| 3.7.3 | End of Life Care |
|
|
References |
|
|
Post Test |
|
|
Assessment Of The Geriatric… |
|
|
Module Objectives |
|
|
Domains of Assessment: Functional Assessment |
|
|
Domains Of Assessment: Psychosocial Health And Functioning |
| 4.3.1 | Informal Caregiving Support Network |
| 4.3.2 | Abuse and Neglect |
| 4.3.3 | Social Support |
| 4.3.4 | Spiritual and Cultural Assessment |
| 4.3.5 | Home Assessment |
|
|
Special Considerations In Assessment |
|
|
Post Test |
|
|
Health Care Policies |
|
|
Module Objectives |
|
|
The Policy-Making Process |
|
|
Financing Health & Long Term Care |
|
|
Quality Of Care Issues In Long Term Care |
|
|
Need And Access Across The Spectrum Of Care |
|
|
References |
|
|
Post Test |
|
|
Exploring Age-Related Body… |
|
|
Cardiovascular System |
| 6.1.1 | Case 1 |
| 6.1.2 | Case 2 |
| 6.1.3 | The Cardiovascular System |
| 6.1.4 | Can These Changes Be Modified? |
| 6.1.5 | Sodium and Activity |
| 6.1.6 | Atherosclerosis |
| 6.1.7 | What Can We Do About The Process? |
| 6.1.8 | Links to Theories of Aging |
| 6.1.9 | Myocardium |
| 6.1.10 | Clinical Implications |
| 6.1.11 | Cellular Calcium |
| 6.1.12 | Functional Changes |
| 6.1.13 | Pulse Wave Velocity |
| 6.1.14 | Additional Functional Changes |
| 6.1.15 | Clinical Significance |
| 6.1.16 | Response to Stress |
| 6.1.17 | Congestive Heart Failure |
| 6.1.18 | Diastolic Versus Systolic Heart Failure |
| 6.1.19 | Case 3 |
| 6.1.20 | Case 3: Points To Consider |
| 6.1.21 | References |
| 6.1.22 | Review Question 1 |
| 6.1.23 | Review Question 2 |
|
|
Endocrine System |
| 6.2.1 | Case 1: Mr. Jones |
| 6.2.2 | Circadian Rhythms |
| 6.2.3 | Hypothalamic-Pituitary and Hypothalamic-Pituitary-Adrenal Axis |
| 6.2.4 | Growth Hormone |
| 6.2.5 | Why Does Growth Hormone Decrease? |
| 6.2.6 | Why is Growth Hormone Important to Our Clinical Practice? |
| 6.2.7 | Is This Good Clinical Practice? |
| 6.2.8 | Case 2: Discussion |
| 6.2.9 | CRH, Adrenocorticotropic Hormone/Corticotropin (ACTH), and Cortisol |
| 6.2.10 | Aging, the Stress Response, Cortisol, and Cognitive Function |
| 6.2.11 | Aldosterone |
| 6.2.12 | Dehydroepiandrosterone (DHEA) |
| 6.2.13 | The Adrenal Medulla |
| 6.2.14 | Hypothalamic-Pituitary-Thyroid Axis |
| 6.2.15 | Posterior Pituitary |
| 6.2.16 | Case 3: Clinical |
| 6.2.17 | Endocrine Pancreas |
| 6.2.18 | What Causes These Changes? |
| 6.2.19 | Can These Changes Be Prevented? |
| 6.2.20 | What Do We See Clinically? |
| 6.2.21 | Discussion Point |
| 6.2.22 | Should Age-Related Changes in Carbohydrate Metabolism Be Treated? |
| 6.2.23 | Summary Case and Evaluation Questions |
| 6.2.24 | References |
| 6.2.25 | Review Question 1 |
| 6.2.26 | Review Question 2 |
|
|
Immune System |
| 6.3.1 | Setting the Stage |
| 6.3.2 | Setting the Stage 2 |
| 6.3.3 | Overview and Background |
| 6.3.4 | What Happens with Age? |
| 6.3.5 | Non-Specific Immunity |
| 6.3.6 | The Physical Barriers |
| 6.3.7 | Acid Contents of the Stomach |
| 6.3.8 | Phagocytosis |
| 6.3.9 | The Macrophage |
| 6.3.10 | The "Natural Killer" and the "LAK" |
| 6.3.11 | Non-Specific Summary |
| 6.3.12 | Specific Immunity |
| 6.3.13 | What Happens to Specific Immunity With Age? |
| 6.3.14 | The Immune Response |
| 6.3.15 | References |
|
|
Musculo-Skeletal System |
| 6.4.1 | Case 1 |
| 6.4.2 | Case 1 Continued |
| 6.4.3 | The Inter-Relationship of the Muscle and Skeletal System |
| 6.4.4 | Muscle Changes and Function with Age |
| 6.4.5 | Changes in Muscle with Age |
| 6.4.6 | Muscle Fibers |
| 6.4.7 | What Are The Physiologic Processes That Cause These Changes? |
| 6.4.8 | What Is The Impact Of These Changes On Function? |
| 6.4.9 | Mobility Changes |
| 6.4.10 | Interventions to Minimize Changes |
| 6.4.11 | Discussion Point |
| 6.4.12 | Joints, Tendons, and Ligaments |
| 6.4.13 | Differences in Cartilage Between Aging and Osteoarthritis |
| 6.4.14 | Skeletal Changes With Age |
| 6.4.15 | Bone Components |
| 6.4.16 | Many Factors Influence Bone Health |
| 6.4.17 | Bone Loss |
| 6.4.18 | General Changes in the Bone with Age |
| 6.4.19 | Factors Influencing Whether a Fracture Will Or Will Not Occur |
| 6.4.20 | Summary Case |
| 6.4.21 | References |
|
|
Neurological System |
|
|
Renal System |
|
|
Post Test |
Module 6: Exploring Age-Related Body Systems Changes6.1: Cardiovascular System6.1.18: Diastolic Versus Systolic Heart FailureAbout 1/3 of patients with symptomatic CHF have a “normal” Ejection Fraction (EF at least >40%) and experience symptoms that are entirely or predominantly the result of diastolic dysfunction. However, about 50-60% of elderly persons with heart failure have adequate ventricular contractile function and are thus experiencing mainly diastolic dysfunction (Kitzman, 2002).
CHF secondary to systolic dysfunction is the result of an impaired inotropic state; this is failure of the heart’s actual pumping capacity—it can’t get blood out. Causes include idiopathic dilated cardiomyopathy, or myocardial infarctions that damage the muscle. CHF secondary to diastolic dysfunction is the result of an impairment in heart’s ability to relax. There is an increase in the ventricular diastolic pressure at any given diastolic volume. The heart doesn’t let blood in well. Causes include restrictive and hypertrophic cardiomyopathies, ischemic states, hypertension, and senile cardiac amyloid. Why is it important? We currently know much more about systolic dysfunction than diastolic dysfunction in terms of treatment, but drugs may differ. Unfortunately, there are currently no data from prospective, randomized, blinded drug trials to guide treatment (Kitzman, 2002). Control of hypertension and minimizing ischemia are important goals. ACE inhibitors and Angiotensin Receptor Blocking agents appear to be indicated for both. While digoxin might be considered in systolic dysfunction, mainly now when there is atrial fibrillation, it may not be as effective in diastolic dysfunction because it increases contractility rather than relaxation. However, some data suggest that it may improve symptoms (Kitzman, 2002). Beta blockers also may be indicated in diastolic dysfunction. Thus in general, much more research is needed in this area to identify the best pharmacotherapeutic approach. However, it is also important to keep in mind that with diastolic dysfunction, venous return and adequate ventricular filling are very important to maintaining cardiac output. Thus there is a fine balance between giving diuretics to minimize symptoms and over-dehydrating the patient which can cause further cardiac dysfunction. |

